IN8BIO, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $10.2M | $17.0M | $16.8M | $14.1M | $7.3M |
| Operating expenses | $19.9M | $30.7M | $30.3M | $28.5M | $14.7M |
| Operating income | -$19.4M | -$30.4M | -$30.0M | -$28.5M | -$14.7M |
| Pretax income | -$19.4M | -$30.7M | — | — | — |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$19.4M | -$30.4M | -$30.0M | -$28.5M | -$14.7M |
| Balance Sheet | |||||
| Current assets | $27.9M | $12.6M | $24.6M | $22.2M | $39.0M |
| Total assets | $32.3M | $20.9M | $33.7M | $33.0M | $42.2M |
| Current liabilities | $3.2M | $3.1M | $5.4M | $5.8M | $2.3M |
| Total liabilities | $4.7M | $6.5M | $8.8M | $10.3M | $4.0M |
| Stockholders' equity | $27.6M | $14.5M | $24.9M | $22.7M | -$38.2M |
| Cash Flow Statement | |||||
| Cash from operations | -$12.7M | -$24.1M | -$23.3M | -$24.1M | -$13.5M |
| Depreciation and amortization | $1.0M | $976,000 | $962,000 | $147,000 | $89,000 |
| Stock-based compensation | $3.2M | $5.0M | $4.4M | $3.5M | $2.2M |
| Capital expenditure | — | — | $0 | $356,000 | $0 |
| Free cash flow | — | — | -$23.3M | -$24.5M | -$13.5M |
Shares outstanding 9.8M
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.